ImmuneOnco Stages $30 Million Hong Kong IPO for Innate/Adaptive Immunity Drugs
publication date: Sep 11, 2023
Last week, Shanghai ImmuneOnco Biotech completed a $30 million IPO on the Hong Kong Stock Exchange to support its portfolio of oncology candidates that exploit innate and adaptive immunity. The company contrasts its portfolio with most other companies that stress adaptive immunity only, which it says causes low response rates and inevitable drug resistance. ImmuneOnco’s lead product, IMM01, is a next-gen CD47-targeted molecule currently in China Phase II clinical trials. IMM01 is a recombinant human SIRPα IgG1 fusion protein that simultaneously blocks a "don't eat me" signal mediated by CD47/SIRPα and activates an "eat me" signal by interacting with FcγRs on macrophages. More details....
Stock Symbol: (HK: 01541)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.